Neuromodulation market seen reaching $12.88B by 2030

The neuromodulation market is projected to grow from $8.45 billion in 2026 to $12.88 billion by 2030, according to The Business Research Company. Rising chronic pain, neurological disorders, AI-assisted systems and home-based therapies are among the main drivers.

Why it matters: - Neuromodulation is moving from a niche treatment area into a larger market for chronic pain and neurological disorders. - The forecast points to sustained demand for minimally invasive, targeted therapies. - The category’s expansion could accelerate adoption of implantable, non-invasive and personalized stimulation systems.

What happened: - The Business Research Company released a neuromodulation market outlook on Aug. 19, 2026. - The report puts the market at $7.62 billion in 2025 and $8.45 billion in 2026. - The company forecasts the market will reach $12.88 billion by 2030. - The report projects a 10.9% CAGR from 2025 to 2026 and 11.1% CAGR from 2026 to 2030. - North America held the largest share of the neuromodulation market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report includes a free sample and the full market report via inline links: Download a free sample and View the full market report.

The details: - The report cites chronic pain, neurological disorders, wider acceptance of minimally invasive treatments, specialized pain management centers and advanced implantable devices as drivers of recent growth. - Looking ahead, the report cites AI-assisted neuromodulation systems, home-based therapies, broader psychiatric and neurological indications, patient-specific stimulation protocols, biomaterial improvements and device miniaturization as growth drivers. - Expected market trends include wider adoption of implantable devices, increased use of non-invasive treatments, smart and programmable stimulators, expansion beyond pain management and more personalized neurotherapy. - Neuromodulation is described as altering nerve activity with electrical or pharmacological agents applied to targeted areas. - The approach is typically reversible and is used to alleviate pain by modulating nerve signals. - The therapy offers a minimally invasive option for chronic pain and other neurological conditions. - The report points to rising healthcare spending worldwide as a key tailwind. - UK data from May 2024 show total healthcare expenditure rose 5.6% in nominal terms in 2023, after 0.9% growth over 2022. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, plus updated graphics and tables.

Between the lines: - The market’s growth profile suggests neuromodulation is gaining broader clinical and commercial acceptance. - AI integration and device miniaturization point to a shift toward more precise and more convenient treatment models. - North America’s lead suggests the region still has the deepest commercial base, while other regions remain growth targets.

What’s next: - The market is expected to keep expanding through 2030 as new indications and treatment formats gain traction. - Continued investment in healthcare and device innovation will likely shape which companies and technologies capture share. - The report’s emphasis on personalized stimulation suggests patient-specific therapy could become a key competitive differentiator.

The bottom line: - Neuromodulation is on a strong growth path, with The Business Research Company forecasting double-digit annual expansion through 2030.